Compare ATRO & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATRO | ZYME |
|---|---|---|
| Founded | 1968 | 2003 |
| Country | United States | United States |
| Employees | 2620 | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 1.8B |
| IPO Year | N/A | 2022 |
| Metric | ATRO | ZYME |
|---|---|---|
| Price | $68.39 | $24.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $86.00 | $38.90 |
| AVG Volume (30 Days) | 631.1K | ★ 646.1K |
| Earning Date | 05-05-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $105,965,000.00 |
| Revenue This Year | $14.92 | $162.82 |
| Revenue Next Year | $8.81 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 38.87 |
| 52 Week Low | $19.90 | $9.03 |
| 52 Week High | $83.96 | $28.49 |
| Indicator | ATRO | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 45.20 | 51.93 |
| Support Level | $47.03 | $22.28 |
| Resistance Level | $82.37 | $27.54 |
| Average True Range (ATR) | 3.42 | 1.28 |
| MACD | -0.54 | -0.03 |
| Stochastic Oscillator | 41.97 | 29.08 |
Astronics Corp supplies products to the aerospace, defense, and electronics industries. The company has two reportable segments namely Aerospace and Test Systems. The aerospace segment serves three primary markets: military, commercial transport, and General Aviation. The Test Systems segment serves the aerospace, defense, and semiconductor markets. The company generates a majority of its revenue from the Aerospace segment. Geographically, it generates a majority of its revenue from the United States.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.